This multi-center trial will be conducted in United States. It is anticipated that the treatment phase of this study will last up to 36 months, including 12 months for enrollment, and a 24-month ixazomib in combination of lenalidomide and dexamethasone (IRD) treatment period (26 cycles) with ixazomib and/or lenalidomide and/or dexamethasone for the last participant enrolled.